Tuesday, February 7, 2023


Biotechnology News Magazine

EDP Biotech Announces New Hire Sam Libby to Lead Rapid Company Growth and Expansion Opportunities

Latest Posts

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and...

NTX1088 is a First-in-Class and highly potent monoclonal antibody directed against PVR (CD155), a transmembrane protein expressed on cancer cells and associated with resistance to PD1 and PDL1 immune checkpoint inhibitors.

TransCure bioServices Offers BioVolume 3D Imaging for Insightful Preclinical Oncology Research

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width.

CLINUVEL Drug Significantly Reduces UV Skin Damage

“Today’s results build upon the decades of research CLINUVEL has conducted into the use of afamelanotide to protect skin from light, with the first evidence that a single dose of the drug has a photoprotective effect in healthy volunteers. These data add to our regulatory dossier for XP while further developing our specialised healthcare products for wider populations at highest risk of UV-induced damage and skin cancer,” Dr Bilbao said.

Deciphex Completes Validation Activities Enabling Veterinary Consultant Pathologists to Perform CLP Peer Review Digitally Using Patholytix

GLP and non-GLP studies can now be digitally peer reviewed by consultant pathologists for CROs and Pharma companies leading to faster study review and reduced backlogs with Drug candidates brought to clinical trials sooner advises Deciphex.

EDP Biotech proudly welcomes Sam Libby as the Company’s Head of Mergers & Acquisitions and Corporate Development. Libby will manage investments, drive merger and acquisition opportunities and develop corporate relationships for the Company. Additionally, Libby will support the execution and expansion of our strategy as the Company is meeting milestones faster than expected and is experiencing rapid growth.

Libby joins the EDP Biotech team with almost a decade of experience in healthcare investment banking, experience in advising clients on mergers and acquisitions, public and private equity financings and other strategic alternatives. He has completed 30+ transactions across various healthcare verticals with a combined valuation of over $20 billion.

“I am very excited to join the EDP Biotech team. I have worked alongside Eric Mayer and EDP’s management team in a banking relationship for some time. I strongly believe in their patient-centered approach and core objective of increasing accessibility to early-stage cancer detection,” said Libby.

“Libby’s experience and breadth of knowledge are paralleled by his philosophy of getting ahead of disease to improve patient lives. These are values deeply shared by EDP Biotech,” said Eric Mayer, CEO of EDP Biotech.

The addition of Libby will add value to the team, accelerate the Company’s growth goals and support the overall mission to improve patient lives.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine